MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Chikungunya: An emerging arthropod borne disease presenting as rhombencephalitis with near complete recovery

    M. Shah, P. Shah, T. Singhal, K. Shetty, R. Syed, A. Aggarwal (Mumbai, India)

    Objective: To report the clinical course and good neurological outcome of severe Chikungunya rhombencephalitis. Background: Chikungunya is an emerging Aedes mosquito borne virus that is…
  • 2022 International Congress

    Gerstmann-Straussler-Scheinker Syndrome Manifesting Levodopa-Responsive Parkinsonism, Levodopa-Induced Dyskinesia, and Abnormal DaT-SPECT

    S. Aradi (Tampa, USA)

    Objective: The objective of this report is to describe previously unreported features in a patient with Gerstmann-Straussler-Scheinker syndrome (GSS) due to the F198S mutation. Background:…
  • 2022 International Congress

    Dorsolateral nigral hyperintensity on 1.5 versus 3T susceptibility-weighted magnetic resonance imaging in neurodegenerative parkinsonism

    B. Heim, A. Grossauer, F. Krismer, W. Poewe, K. Seppi (Innsbruck, Austria)

    Objective: In contrast to their 1.5T counterparts, high field MRI scanners are often unavailable in clinical routine, particularly in primary care facilities and underserved regions.…
  • 2022 International Congress

    Impact on non-motor symptoms, cognition, and QoL after 1-year of DBS for Parkinson’s Disease: An interim report from the ADROIT NAPA sub-study

    M. Poetter-Nerger, S. Groppa, O. Adam, A. Schnitzler, M. Navas Garcia, B. Cheeran, L. Himes, M. Frassica, A. Gharabaghi (Hamburg, Germany)

    Objective: To present the impact on cognition, quality of life, and non-motor symptoms after 1-year of DBS for Parkinson’s Disease through the ADROIT post-market study.…
  • 2022 International Congress

    Paliperidone induced neuroleptic malignant syndrome treated with electroconvulsive therapy and continuous apomorphine: A case report

    M. Gultekin, S. Benli (Kayseri, Turkey)

    Objective: Neuroleptic malignant syndrome (NMS) is a neurological emergency that is often induced by antipsychotic drugs. NMS may be mortal if left untreated. Background: In…
  • 2022 International Congress

    Silencing dopamine neurons during sleep slows disease progression in parkinsonian mice

    C. Meng, G. Cui (Research Triangle Park, USA)

    Objective: To develop a treatment to stop or slow the progression of Parkinson's disease. Background: Parkinson’s disease (PD) is believed to be caused by the…
  • 2022 International Congress

    Neuroanatomical underpinnings of apathy in Parkinson’s Disease

    C. Le Heron, E. Huey, N. Vanegas-Arroyave, Y. Gazes, S. Lee (New Zealand)

    Objective: To investigated the integrity of white matter tracts within basal ganglia-frontal networks in PD patients with and without apathy, and relate these to specific…
  • 2022 International Congress

    The mGlu2 positive allosteric modulator BINA extends enhances low dose L-DOPA anti-parkinsonian action in the MPTP-lesioned marmoset

    C. Kwan, I. Frouni, S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To determine the effect of positive allosteric modulation of the metabotropic glutamate type 2 (mGlu2) receptor in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset using a low…
  • 2022 International Congress

    Botulinum Toxin Therapy for Medication and DBS Refractory Foot Dystonia of Parkinsonism

    E. Zinoviev, M. Ganapathy, M. Siddiqui (Winston-Salem, USA)

    Objective: To determine efficacy and safety of BTX therapy in patients with medically refractory foot dystonia secondary to Parkinson’s disease (PD) or atypical Parkinsonism (AP)…
  • 2022 International Congress

    A Patient-Centered Outcomes Survey in Parkinson’s Disease: Results of Cognitive Pre-Testing

    D. Shah-Zamora, J. Karl, M. Tosin, G. Pal, G. Stebbins, C. Goetz, L. Verhagen (Chicago, USA)

    Objective: To validate the Rush Parkinson's Disease Patient-Centered Outcomes Questionnaire (RUSH-PCO-Q). Background: The RUSH-PCO-Q aims to address the lack of patient-centered outcomes in the field…
  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 153
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley